This company has been marked as potentially delisted and may not be actively trading. Aquinox Pharmaceuticals (AQXP) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock AQXP vs. DYN, AUPH, SNDX, BGM, WVE, OPK, ETNB, COLL, MLYS, and HROWShould you be buying Aquinox Pharmaceuticals stock or one of its competitors? The main competitors of Aquinox Pharmaceuticals include Dyne Therapeutics (DYN), Aurinia Pharmaceuticals (AUPH), Syndax Pharmaceuticals (SNDX), Qilian International Holding Group (BGM), Wave Life Sciences (WVE), OPKO Health (OPK), 89bio (ETNB), Collegium Pharmaceutical (COLL), Mineralys Therapeutics (MLYS), and Harrow (HROW). These companies are all part of the "medical" sector. Aquinox Pharmaceuticals vs. Dyne Therapeutics Aurinia Pharmaceuticals Syndax Pharmaceuticals Qilian International Holding Group Wave Life Sciences OPKO Health 89bio Collegium Pharmaceutical Mineralys Therapeutics Harrow Aquinox Pharmaceuticals (NASDAQ:AQXP) and Dyne Therapeutics (NASDAQ:DYN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership, media sentiment, community ranking and earnings. Do analysts rate AQXP or DYN? Dyne Therapeutics has a consensus target price of $47.46, indicating a potential upside of 320.76%. Given Dyne Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Dyne Therapeutics is more favorable than Aquinox Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aquinox Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Dyne Therapeutics 0 Sell rating(s) 1 Hold rating(s) 12 Buy rating(s) 2 Strong Buy rating(s) 3.07 Which has stronger earnings and valuation, AQXP or DYN? Aquinox Pharmaceuticals has higher revenue and earnings than Dyne Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAquinox Pharmaceuticals$25M13.65-$31.58MN/AN/ADyne TherapeuticsN/AN/A-$235.94M-$3.35-3.37 Does the media favor AQXP or DYN? In the previous week, Dyne Therapeutics had 12 more articles in the media than Aquinox Pharmaceuticals. MarketBeat recorded 12 mentions for Dyne Therapeutics and 0 mentions for Aquinox Pharmaceuticals. Dyne Therapeutics' average media sentiment score of 0.56 beat Aquinox Pharmaceuticals' score of 0.00 indicating that Dyne Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Aquinox Pharmaceuticals Neutral Dyne Therapeutics Positive Which has more volatility and risk, AQXP or DYN? Aquinox Pharmaceuticals has a beta of -7.37, meaning that its stock price is 837% less volatile than the S&P 500. Comparatively, Dyne Therapeutics has a beta of 1.21, meaning that its stock price is 21% more volatile than the S&P 500. Do institutionals and insiders hold more shares of AQXP or DYN? 71.7% of Aquinox Pharmaceuticals shares are held by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are held by institutional investors. 4.0% of Aquinox Pharmaceuticals shares are held by company insiders. Comparatively, 20.8% of Dyne Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the MarketBeat Community prefer AQXP or DYN? Aquinox Pharmaceuticals received 255 more outperform votes than Dyne Therapeutics when rated by MarketBeat users. However, 77.19% of users gave Dyne Therapeutics an outperform vote while only 71.88% of users gave Aquinox Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAquinox PharmaceuticalsOutperform Votes29971.88% Underperform Votes11728.13% Dyne TherapeuticsOutperform Votes4477.19% Underperform Votes1322.81% Is AQXP or DYN more profitable? Aquinox Pharmaceuticals' return on equity of -30.13% beat Dyne Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aquinox PharmaceuticalsN/A -30.13% -28.08% Dyne Therapeutics N/A -57.46%-51.62% SummaryDyne Therapeutics beats Aquinox Pharmaceuticals on 10 of the 15 factors compared between the two stocks. Get Aquinox Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AQXP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AQXP vs. The Competition Export to ExcelMetricAquinox PharmaceuticalsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$341.33M$6.74B$5.47B$7.80BDividend YieldN/A3.11%5.42%4.24%P/E RatioN/A7.2722.3118.46Price / Sales13.65241.32394.17104.18Price / CashN/A65.8538.1834.62Price / Book4.696.356.724.21Net Income-$31.58M$143.17M$3.22B$248.18M Aquinox Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AQXPAquinox PharmaceuticalsN/A$14.50-5.9%N/A-48.6%$341.33M$25M0.008DYNDyne Therapeutics3.3003 of 5 stars$9.33+14.2%$47.46+408.7%-54.4%$1.06BN/A-2.62100Upcoming EarningsShort Interest ↑High Trading VolumeAUPHAurinia Pharmaceuticals2.8066 of 5 stars$7.66-1.2%$11.50+50.1%+62.9%$1.05B$235.13M-51.06300Upcoming EarningsPositive NewsSNDXSyndax Pharmaceuticals3.6477 of 5 stars$11.93+3.4%$36.20+203.4%-36.3%$1.03B$23.68M-3.29110Upcoming EarningsNews CoveragePositive NewsBGMQilian International Holding GroupN/A$10.52-4.4%N/AN/A$1.02B$25.10M0.00298News CoverageWVEWave Life Sciences4.3007 of 5 stars$6.12+3.4%$22.18+262.4%+46.6%$939.33M$108.30M-5.51240OPKOPKO Health4.4669 of 5 stars$1.37-3.5%$2.75+100.7%+11.9%$920.02M$713.14M-7.214,200Upcoming EarningsShort Interest ↓Positive NewsETNB89bio3.0084 of 5 stars$6.27+3.5%$27.56+339.5%-10.4%$915.32MN/A-2.1540Gap DownCOLLCollegium Pharmaceutical4.0228 of 5 stars$26.91-0.4%$43.60+62.0%-26.2%$864.67M$631.45M11.60210Positive NewsMLYSMineralys Therapeutics2.4162 of 5 stars$13.24-0.8%$33.00+149.2%+14.2%$858.96MN/A-3.6428Short Interest ↑HROWHarrow2.5149 of 5 stars$23.24-3.1%$60.50+160.3%+134.1%$828.60M$199.61M-24.72182Positive News Related Companies and Tools Related Companies DYN Competitors AUPH Competitors SNDX Competitors BGM Competitors WVE Competitors OPK Competitors ETNB Competitors COLL Competitors MLYS Competitors HROW Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AQXP) was last updated on 4/29/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aquinox Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Aquinox Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
